Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,159 shares of the biopharmaceutical company’s stock after selling 126 shares during the period. Freedom Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $319,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Huntington National Bank raised its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $26,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $42,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $45,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ALNY. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Piper Sandler reiterated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Raymond James boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $253.07 on Friday. The firm has a fifty day moving average of $271.07 and a 200-day moving average of $241.00. The company has a market cap of $32.64 billion, a price-to-earnings ratio of -96.59 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same period last year, the firm earned $1.15 earnings per share. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,370 shares of company stock valued at $2,100,703 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.